نتایج جستجو برای: sustained virological response

تعداد نتایج: 1045619  

Journal: :Saudi medical journal 2009
Muhammad A Ayyub Soha A El-Moursy Adel M Khazindar Fahd A Abbas

The objective of this case series was to determine the efficacy and safety of combined treatment with ribavirin and peginterferon alpha-2a in sickle cell disease (SCD) patients with chronic hepatitis C virus (HCV) hepatitis. Eight patients in King Abdulaziz Hospital & Oncology Center, Jeddah, Kingdom of Saudi Arabia from 2003 and 2006 with chronic HCV infection were treated with peginterferon a...

Journal: :Frontiers in bioscience 2011
Runu Chakravarty

Chronic Hepatitis B (HBV) and Hepatitis C (HCV) virus infections are global health problems which may cause cirrhosis and even hepatocellular carcinoma. Hepatitis D virus (HDV) though a satellite virus of HBV, can also cause chronic infection. Serologic and molecular tools are needed for the diagnosis, monitoring and therapeutic management of chronic viral hepatitis associated with HBV, HDV and...

2013
Yoshio Aizawa Noritomo Shimada Hiroshi Abe Nobuyoshi Seki Yuta Aida Haruya Ishiguro Makiko Ika Keizo Kato Akihito Tsubota

BACKGROUND Abnormal serum lipid profiles have been noted in patients with chronic hepatitis C virus (HCV) infection. Moreover, many reports suggest that serum lipoprotein profiles are more profoundly distorted in patients with HCV G1b infection who have an unfavorable response to pegylated interferon (peg-IFN) plus ribavirin (RBV) combination therapy. However, after the discovery of single nucl...

2016
Dorota Zarębska-Michaluk Dariusz Lebensztejn Magdalena Chrapek Katarzyna Paluch Piotr Stępień Wiesław Kryczka

AIM OF THE STUDY To assess predictors of sustained virological response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 3 treated with standard therapy. MATERIAL AND METHODS We retrospectively investigated data of 116 consecutive treatment-naïve patients chronically infected with HCV genotype 3, treated with pegylated interferon alpha (PegIFNα) and ribavirin (RBV) for 24 weeks...

2010
Nan Xiao Shuang Shi Hui Zhuang

BACKGROUND Two kinds of peginterferons, peginterferon-α2a (PEG-IFN-α2a) and peginterferon-α2b (PEG-IFN-α2b), are used in the treatment of chronic hepatitis C virus (HCV) infection. However, it is unclear which is better in terms of virological responses and patient compliance. We conducted a meta-analysis to assess which peginterferon was better when used with ribavirin. METHODS Relevant clin...

2016
Valerio Giannelli Maurizio Simmaco Luana Lionetto Giovanna Gentile Michela Giusto Francesca Romana Ponziani Antonio Gasbarrini Ubaldo Visco-Comandini Adriano Pellicelli Stefano Ginanni Corradini Antonio Molinaro Elisa Biliotti Manuela Merli Gloria Taliani

The genetic polymorphism of Equilibrative Nucleoside Transporter 1 [ENT1] is involved in ribavirin cellular uptake and it could positively enhance antiviral treatment response. The liver transplant setting offers the unique opportunity to selectively observe the effect(s) of the donor liver ENT1 gene on HCV treatment outcome. We aimed at studying donor polymorphism of ENT1 and HCV therapy outco...

2012
Tatsuo Miyamura Tatsuo Kanda Shingo Nakamoto Shuang Wu Xia Jiang Makoto Arai Keiichi Fujiwara Fumio Imazeki Osamu Yokosuka

It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. In the present study, we examined how ITPA and IL28B genotypes have clinical impacts on treatment-induced hematotoxicities and ...

2014
Hideyuki Tamai Ryo Shimizu Naoki Shingaki Yoshiyuki Mori Shuya Maeshima Junya Nuta Yoshimasa Maeda Kosaku Moribata Yosuke Muraki Hisanobu Deguchi Izumi Inoue Takao Maekita Mikitaka Iguchi Jun Kato Masao Ichinose

The aim of the present study was to predict sustained virological response (SVR) to telaprevir with pegylated interferon (PEG-IFN) and ribavirin using viral response within 2 weeks after therapy initiation. Thirty-six patients with genotype 1 hepatitis C virus (HCV) and high viral load were treated by telaprevir-based triple therapy. SVR was achieved in 72% (26/36) of patients. Significant diff...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید